Archives — Current Month (33)
The Perfect Gold Stock for Revivalists (12/15/2017)
Technical analyst Clive Maund charts a young gold company that he believes "is going places."
Cannabis Biotech Stock Starting to Advance Again (12/15/2017)
A technical analysis by Clive Maund on CliveMaund.com has a Buy on this cannabis biotech stock.
New Uranium Assays Improve 'Resource Confidence' (12/14/2017)
David Talbot, an analyst with Eight Capital, outlined recent drill results from this energy company's flagship asset.
Craig Stanley, an analyst with Eight Capital, took a look at the terms and potential of this mining company's prospective transactions in Ontario.
Metallic Minerals Catches the Silver Ring (12/14/2017)
Silver is cheap right now, says Bob Moriarty of 321 Gold, who profiles a company in the Yukon that he says is delivering world-class exploration results.
Exploration is just beginning for this oil and gas E&P with large tracts of prime land in the Permian Basin in Texas.
Ed Arce, an analyst with H.C. Wainwright & Co., explained the positive elements of this drug developer's recently released clinical trial data and why they did not warrant the market reaction they got.
Bitcoin Total Wipeout Alert (12/13/2017)
Technical analyst Clive Maund discusses why he thinks Bitcoin is about to take a dive.
Guyana Shield Is Host to Multiple Gold Deposits (12/12/2017)
As two Guyana projects begin commercial gold production, a new mineral resource estimate is in the works for a third project.
A flagship Nevada project is showing results and the company anticipates commencing commercial production in the first quarter of 2018.
Gold Major to Increase Dividend by 50% in 2018 (12/11/2017)
BMO Capital Markets reported on this miner's outlook for 2018 and beyond.
Jack Chan's Weekly Precious Metals Market Update (12/11/2017)
Technical analyst Jack Chan charts the latest movements in the gold and silver markets.
Cryptojunkies: Beware the Ides of December (12/11/2017)
As Bitcoin futures are set to begin trading next week, precious metals expert Michael Ballanger discusses movements in gold and cryptocurrencies.
Keith Barron Wants to Mine U3O8 'Cheep' (12/11/2017)
More mining companies should follow the example of the garimpeiro miners of Brazil who mine until they fail to make a profit, says Bob Moriarty of 321 Gold, who discusses one gold and one uranium company that may be changing the paradigm.
Drill results from a Nevada lithium project caught the attention of The Critical Investor.
The Critical Investor provides an update on this zinc explorer's latest drill results.
A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research.
Cormark Securities provided an update on this company's gold project in central Wyoming.
Biotech Delivers 'Great' Phase 2 Data in NASH (12/07/2017)
John McCamant of the Medical Technology Stock Letter raised his target price on this company given the earning potential of a once-a-day oral treatment for liver disease in what could be a $35 billion market.
With an advanced project being looked at by potential partners and a newer project producing precious metal results, several analysts rate this precious metals explorer a "Buy."
Multiple projects are showing positive and possible expansions for this gold miner.
Shining a Light on an Out-of-Favor Oil Stock (12/07/2017)
Technical analyst Clive Maund charts an oil and gas explorer that he believes is under the radar of most investors.
This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts.
David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm.
Another Uranium Company to Slash Production in 2018 (12/05/2017)
A BMO Capital Markets report describes the implications of this cutback in production for the uranium market.
Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies.
Will 2+2=8 For Columbus Gold? (12/05/2017)
Bob Moriarty of 321 Gold discusses why he believes a spinout could be a win for investors.
Technical analyst Jack Chan charts the latest moves in the gold and silver markets, as well as the one-day fluctuations of a gold major.
Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation.
As farming becomes increasingly centralized, the need for precise agricultural data grows. Streetwise Reports spoke with Rick Mills, founder of Ahead of the Herd, and Fabrice Taylor, publisher of President's Club, on the fusion of drone-supplied data and data analytics.
Peter Epstein, founder of Epstein Research, evaluates Centenera Mining Corp.'s Esperanza copper-gold porphyry project.
Silver and Gold Bottom Soon (12/01/2017)
Gold and silver are on track to hit a yearly low this December, as they have for the past five years, says Bob Moriarty of 321 Gold, who explains his reasoning and why he welcomes these moves.
The True Meaning of Bitcoin's 'Success' (12/01/2017)
Precious metals expert Michael Ballanger discusses Bitcoin, currency devaluation, and gold and silver.
|"The total raised from CGT's Allegiant placement came in at $4.2M."|
|"Drill results from RPM's Florida Canyon will boost the balance sheet."|
|"KDX announced positive initial drill results from Hatter Graben."|
|"BAR has a serially successful team doing what it does best in the area it knows best with several significant discoveries already in hand."|
|"SEA's Iron Cap is likely to expand beyond 6–8 Moz Au and 2–2.5 Blb Cu."|